IC
CRNX icon

Innealta Capital’s Crinetics Pharmaceuticals CRNX Stock Holding History

Innealta Capital’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-36
Closed -$1.61K – 498
2024
Q2 		$1.61K Buy
+36
New +$1.66K ﹤0.01% 1160

Other funds holding CRNX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Innealta Capital's CRNX Position: Q3 2024 in Review

Innealta Capital sold out of Crinetics Pharmaceuticals (CRNX) in Q3 2024, closing a stake of 36 shares — an estimated $1.61K sold.

Innealta Capital first reported a position in CRNX in Q2 2024 and held it in 1 quarter. The position peaked at $1.61K in Q2 2024. 235 funds tracked by Wall St. Rank hold CRNX as of Q3 2024.

  • Innealta Capital reported no remaining Crinetics Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Innealta Capital sold 36 Crinetics Pharmaceuticals shares in Q3 2024, an estimated $1.61K.
  • Innealta Capital first reported a position in Crinetics Pharmaceuticals in Q2 2024 and held it in 1 quarter.
  • Innealta Capital's Crinetics Pharmaceuticals position peaked at $1.61K in Q2 2024.
  • 235 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q3 2024.

Based on Innealta Capital's 13F filing for Q3 2024, filed 29 Oct 2024.